<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03156855</url>
  </required_header>
  <id_info>
    <org_study_id>201506129MINC</org_study_id>
    <nct_id>NCT03156855</nct_id>
  </id_info>
  <brief_title>Sequential Therapy Versus Quadruple Therapy in H. Pylori Eradication</brief_title>
  <official_title>Comparison of the Efficacy of Sequential Therapy and Bismuth Quadruple Therapy in the First Line and Second Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>E-DA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital Hsin-Chu Branch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiayi Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to

        1. compare the eradication rates and long term re-infection rates of sequential therapy for
           14 days versus bismuth quadruple therapy for 10 days in the first line and second line
           treatment

        2. assess the impact of antibiotic resistance and CYP2C19 polymorphism on the eradication
           rate of these regimens

        3. assess the impact of these eradication regimens on the antibiotic resistance and
           microbiota of the gut flora

        4. assess the impact of eradication therapy on the metabolic factors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori infection has been shown to be associated with the development of gastric
      cancer and peptic ulcer diseases. Eradication of H. pylori infection reduces the risk of
      gastric cancer and recurrence of peptic ulcer disease. However, the eradication rate of
      clarithromycin-based triple therapy has been declining in recent years, probably related to
      the increasing resistant rate to clarithromycin. Sequential therapy for 10 days has been
      shown to be more effective than triple therapy for 7 and 10 days. The investigators further
      demonstrated that sequential therapy given for 14 days was superior to triple therapy given
      for 14 days. Recently, the investigators also found that bismuth quadruple therapy given for
      10 days appeared to be more effective than triple therapy given for 14 days in the first line
      therapy. However, whether sequential therapy given for 14 days is more effective than bismuth
      quadruple therapy or triple therapy for 14 days remains unknown.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate: determined by urea breath test (13C-UBT, according to ITT analysis)</measure>
    <time_frame>6 weeks</time_frame>
    <description>No eradicated divided by total cases by intention to treat analysis. 13C-UBT will be used to determine the H. pylori status at least 6 weeks after completion of treatment. A delta value of &gt; 4 units will be defined as positive for H. pylori infection as our previous studies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse effect: occurrence of any adverse effect during the treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>adverse effects related to treatment by per protocol analysis. The patients will be informed of the common side effects from the studied drugs prior to therapy. They will also be asked to record these symptoms during treatment. A standardized interview at the outpatient clinic at the end of treatment will be arranged. The adverse events and compliance will be assessed by the research staffs with pre-defined case report form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of antibiotic resistance</measure>
    <time_frame>2 weeks, 8 weeks, 1 year</time_frame>
    <description>changes of antibiotic resistance of E. coli by per protocol analysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>changes of gut microbiota</measure>
    <time_frame>2 weeks, 8 weeks, 1 year</time_frame>
    <description>changes of gut microbiota before and after HP eradication by per protocol analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">620</enrollment>
  <condition>Helicobacter</condition>
  <arm_group>
    <arm_group_label>sequential therapy for 14 days (S14)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 day sequential therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bismuth quadruple therapy (Q10)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bismuth quadruple therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14-day sequential therapy</intervention_name>
    <description>D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days</description>
    <arm_group_label>sequential therapy for 14 days (S14)</arm_group_label>
    <other_name>S14</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth quadruple therapy</intervention_name>
    <description>D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days</description>
    <arm_group_label>bismuth quadruple therapy (Q10)</arm_group_label>
    <other_name>Q10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. H. pylori infected patients na√Øve to eradication therapies will be eligible in this
        study.

        Exclusion Criteria:

          1. children and teenagers aged less than 20 years,

          2. history of gastrectomy,

          3. gastric malignancy, including adenocarcinoma and lymphoma,

          4. previous allergic reaction to antibiotics (bismuth, amoxicillin, metronidazole,
             clarithromycin, tetracycline) and PPI (esomeprazole),

          5. contraindication to treatment drugs,

          6. pregnant or lactating women,

          7. severe concurrent disease,

          8. concomitant use of clopidogrel, or (9) Unwilling to accept random assignment of
             subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Shiang Wu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyh-Ming Liou, MD, PhD</last_name>
    <email>dtmed046@pchome.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chiayi Christian Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Po-Yuei Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Hsinchu Branch</name>
      <address>
        <city>Hsinchu</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Feng Hsu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>E-DA University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-Yang Chang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jyh-Ming Liou</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyh-Ming Liou, MD, PhD</last_name>
      <phone>886972651883</phone>
      <email>jyhmingliou@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veteran General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing-Chuang Luo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital, Taitung branch</name>
      <address>
        <city>Taitung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Chung Bair</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Yunlin County</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Ren Fang, MD</last_name>
      <phone>886972655474</phone>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>H. pylori eradication</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

